Brain Metastases News and Research

RSS

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

14 Sep 2026

Laser treatment may extend survival in glioblastoma patients

For patients facing a diagnosis of glioblastoma - one of the most aggressive and devastating forms of brain cancer - the standard path forward has long meant an invasive open-skull surgery and a daunting prognosis.

17 Aug 2026

AI-based methods help uncover hidden roots of tumor metastasis

A cancerous tumor is not a single enemy. It is made up of many different cell populations that can behave in very different ways.

12 Aug 2026

Preoperative radiation boosts immunotherapy response in brain metastases

A new study led by researchers at The University of Texas MD Anderson Cancer Center demonstrated that pre-operative radiation therapy for brain metastases not only targets tumor cells directly but also can activate immune pathways that can make tumors more receptive to immunotherapy.

17 Jun 2026

AI accurately measures mesothelioma tumors for better treatment decisions

Physicians and researchers at the Netherlands Cancer Institute have developed an AI model that outperforms physicians at evaluating treatment response in pleural mesothelioma.

17 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

Implanted collagen tiles double survival for brain metastasis patients

A multicenter clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

30 May 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.

1 Apr 2026

Study identifies a promising strategy to treat brain metastases

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer.

2 Mar 2026

Stereotactic radiation improves quality of life in patients with brain metastases

In a Phase 3 randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better day to day function when compared with whole brain radiation

19 Feb 2026

Soluble E-cadherin drives brain metastasis in aggressive inflammatory breast cancer

Researchers at The University of Texas MD Anderson Cancer Center have identified a targetable driver of brain metastases in patients with aggressive inflammatory breast cancer.

28 Jan 2026

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Unexpected traces of bacteria found within brain tumors

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors.

14 Nov 2025

New drug can have a promising effect in cancer patients with active brain metastases

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of various tumor types.

28 Oct 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025

Brain Metastases News and Research

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Laser treatment may extend survival in glioblastoma patients

AI-based methods help uncover hidden roots of tumor metastasis

Preoperative radiation boosts immunotherapy response in brain metastases

AI accurately measures mesothelioma tumors for better treatment decisions

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

Implanted collagen tiles double survival for brain metastasis patients

Damon Runyon supports young scientists driving cancer research innovation

Targeted therapy pralsetinib improves outcomes in RET fusion-positive NSCLCs

Study identifies a promising strategy to treat brain metastases

Stereotactic radiation improves quality of life in patients with brain metastases

Soluble E-cadherin drives brain metastasis in aggressive inflammatory breast cancer

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Unexpected traces of bacteria found within brain tumors

New drug can have a promising effect in cancer patients with active brain metastases

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News